Peer-influenced content. Sources you trust. No registration required. This is HCN.
MedCentral
Baxdrostat significantly reduced seated systolic blood pressure compared to placebo in 796 patients, with placebo-adjusted reductions of 9.8 mmHg and 8.7 mmHg at the 2 mg and 1 mg doses respectively, without impacting cortisol levels.
Cardiology April 24th 2026
Ophthalmology Management
Reproxalap is an investigational drug candidate for the treatment of dry eye disease.
Ophthalmology March 24th 2026
GoodRx for Healthcare Professionals
If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.
Endocrinology, Diabetes, Metabolism March 13th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS